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ABSTRACT 
Dabrafenib is one of the most widely used of the new generation of targeted anti-cancer drugs. 
However, its therapeutic window varies for different patients and so there is an unmet need for methods 
to monitor the dose of drug which the patient receives and at the specific site where it acts. In the case 
of cancers, it is critical to measure the concentration of drug not just in the bloodstream overall, but in 
or near tumours, as these will not be the same over multiple time periods. A novel sensor based on an 
optical fibre long period grating (LPG) modified with a molecular imprinted polymer (MIP) has been 
developed with the ultimate aim of achieving minimally invasive measurements of Dabrafenib at the 
tumour site. A molecularly imprinted polymer specific for Dabrafenib was coated on a 
methacryloylalkoxysilane-functionalised optical fibre long period grating. In vitro experimental 
results demonstrate that the Dabrafenib sensitivity is 15.2pm/(μg·mL-1) (R2=0.993) with a limit of 
detection (LoD) of 74.4 μg·mL-1 in serum solution. Moreover, the proposed sensor shows selective 
response to Dabrafenib over structurally similar 2-Aminoquinoline.  
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1. Introduction  
The mitogen-activated protein kinase (MAPK) pathway inhibitor Dabrafenib is one of the most 
widely used of the new generation of targeted anti-cancer drugs, with demonstrated efficacy in treating 
patients with melanoma 1 2. Dabrafenib has specific activity against BRAFV600-mutated melanoma 
cells 3, but although many patients are well-treated with this agent, nearly half of those administered 
with BRAF inhibitors, or the related MEK inhibitors, exhibit progression of disease within ~7 months 
after treatment starts 2. Although the mechanisms by which resistance to BRAF inhibitors develop are 
complex and multifaceted, important contributors include the dosing regime and the duration of 
exposure, as prolonged dosing below the therapeutic efficacy threshold inherently selects for resistant 
phenotypes. Since the therapeutic window varies for different patients and indeed across a wide range 
of therapeutics in addition to Dabrafenib, there is accordingly an urgent need for methods to monitor 
the dose of drug which the patient receives at the specific site where it acts. In the case of cancers, it 
is thus critical to measure the concentration of drug not just in the bloodstream overall, but in or near 
tumours, as these will not be the same over multiple time periods. In addition, it would be highly 
advantageous if any such measurement could be made in a minimally-invasive manner, and with 
methods that might be adaptable not just to Dabrafenib and BRAF inhibitors, but also to other drug 
types for application beyond cancer, such as infection and immunotherapies.  
In recent years, the techniques of molecular imprinting have been adapted beyond their well-
established routes to selective separations, and particularly towards some innovative applications in 
sensing and analysis 4. Imprinted polymers are increasingly being used as robust and versatile synthetic 
alternatives to antibodies for sensitive detection of analytes ranging from environmental contaminants 
through to anti-microbial drugs. The ability to ‘design-in’ a recognition site for a specific analyte in a 
synthetic receptor is obviously appealing when compared to raising an antibody for the same target by 
more conventional methods. However, converting a molecular recognition event into a signal which 
can be used to report that event has, in the past, been a major difficulty for imprinted polymers, which 
have often been prepared as monoliths that are difficult to process. Therefore, much recent research in 
the field of imprinted polymers has been concerned with generating the materials in a format which 
allows coupling to sensors or detection systems in a simple and rapid way, and in a manner which 
allows adaptation to multiple sensor formats 5,6. In particular, we and others have been developing 
methods to link imprinted polymers to optical fibre long period grating (LPG) sensors, as these offer 
the possibility for fast, sensitive and durable analytics in an inexpensive and adaptable format 7, 8, 9. A 
long period grating is a periodic modulation of the refractive index of the core of a single mode optical 
fibre that couples light from the fundamental core mode to a co-propagating cladding mode enabling 
access to an evanescent wave that is highly sensitive to refractive index 10, 11, 12, 13. Significant 
advantages of LPG optical fibre sensors over other types of optical fibre sensors such as tapered, 
intensity based and multimode interferometers are their mechanical robustness and wavelength 
encoded sensor output making them ideal candidates for practical bio-medical applications 14.  
In this paper we describe polymers imprinted with Dabrafenib and a model structural analogue; 
their preparation as coatings for LPG sensors; and the demonstration of their ability to generate signals 
enabling detection and quantification of Dabrafenib against its structural analogue in serum-containing 
samples. We show that the molecular imprinting process can be carried out on a 
methacryloylalkoxysilane-functionalised fibre in the presence of Dabrafenib and an analogue, and that 
incubation of the coated fibres in the presence of Dabrafenib leads to detectable and differentiated 
wavelength shifts in attenuated total reflectance IR (ATR-IR) spectra from the surface of the fibres. 
This process is shown schematically in Figure 1. 
 
Figure 1: Schematic of the format of LPG fibres (A) and their synthesis (B), with the format of the detection system outlined in (C).   In 
(D) are shown the monomers and templates used to form the polymers, while in (E) and (F), respectively, indicate the response to 
binding of Dabrafenib, and the change in wavelength shift as Dabrafenib and an analogue, 2 aminoquinoline are added to solutions 
containing the imprinted polymer coated  LPGs 
These data are the first promising examples of BRAF inhibitor detection by a coated LPG fibre 
system and mark the initial stages towards a new minimally-invasive monitoring system for 
therapeutics in patients in real-time.  
 
2. Materials and Methods  
2.1 Materials 
Sulfuric acid (H2SO4), Hydrogen peroxide (H2O2) solution (30%wt in H2O), 3-(Trimethoxysilyl) 
propyl methacrylate (TMSPMA), Methanol, Acetic acid, Chloroform (CHCl3), 2,2-Dimethoxy-2-
phenylacetophenone (DMPA), Ethylene glycol dimethacrylate (EGDMA), Poly(ethylene glycol) 
methacrylate (Mn = 500 gmol
-1, PEGMA), Methacrylic acid (MAA), 2-Aminoquinoline (2-AQ), Fetal 
bovine serum (FBS) were purchased from Sigma-Aldrich, UK. Dimethyl sulfoxide (DMSO) was 
purchased from Honeywell, UK. Dabrafenib was purchased from Adooq bioscience, USA. All the 
chemicals were of analytical grade and used without further purification. Deionised water (DI-water) 
was obtained from water purification system (PURELAB Option S/R, ELGA). Phosphate buffered 
saline (PBS) was freshly prepared by dissolving PBS tablets (Oxoid, UK) in DI-water, which 
comprised Sodium chloride (8.0 mg mL-1), Potassium chloride (0.2 mg mL-1), Disodium hydrogen 
phosphate (1.15 mg mL-1), Potassium dihydrogen phosphate (0.2 mg mL-1), pH 7.3 ±0.2, at 25°C.    
   
2.2 Instrumentation 
Fourier transform infrared spectrometry (FTIR) was performed using a Cary 630 spectrometer with 
wavenumber accuracy of 0.05 cm-1. Measurements were performed at 25°C, with 64 scans per sample, 
after subtracting a background spectrum measured over an average of 16 scans between 4000 – 650 
cm-1. The spectra from the LPG were measured using a CCD spectrometer (Ocean Optics, HR4000, 
UK) with 0.11 nm wavelength accuracy and a tungsten-halogen light source (Ocean Optics, HL-2000, 
UK).   
2.3 Sensor fabrication and functionalization   
An LPG of length 30 mm and with a grating period of 112 µm was fabricated in boron-germanium 
co-doped optical fibre (Fibrecore PS750, Ø: 250 µm, single-mode with cut-off wavelength of 670 nm) 
using a custom made amplitude mask and side-illuminating the optical fibre by the output from a 
ultraviolet radiation (operating at wavelength of 266 nm, 100 ns pulse duration, 12 mW power) of a 
frequency-quadrupled Nd:YAG laser. During the fabrication process, light is launched through the 
fibre and the transmitted spectrum recorded at a 1 Hz sampling frequency. The LPG period was 
selected for operating at or near the phase matching turning point (PMTP), which ensures the highest 
sensitivity 10. 
2.4 Preparation of imprinted LPG fibres 
Piranha solution was prepared by slowly adding 30% hydrogen peroxide into sulfuric acid as 1:3 (v/v). 
15. The region of the optical fibre containing the LPG was initially treated with Piranha solution for 30 
mins. After washing with deionized water (15 MΩ cm) and drying with a stream of N2 gas, the LPG 
was then modified by silanizing in a 5% solution of 3-(trimethoxysilyl) propyl methacrylate in 
acidified methanol/H2O (95/5, v/v) for 1 h 
17. The fibre was then washed with methanol and water 
repeatedly in an ultrasonic bath. The pre-polymerization solution was prepared by dissolving 
Dabrafenib (10.4 mg, 20 µmol), MAA (5.2 µL, 61.7 µmol), EGDMA (79.2 µL, 420 µmol) and 
PEGMA (6.5 µL, 14.3 µmol) and DMPA (20 mg, 78.1 µmol) in 1 mL chloroform. Subsequently, the 
mixture was sonicated for 10 min and degassed by bubbling with N2 for 20min. The fibre was 
immersed into the freshly prepared pre-polymerization solution. The fibre was then withdrawn and 
exposed to UV irradiation (XX-15 Bench Lamp Fixture, 365 nm) for 5 h and left at room temperature 
overnight. Finally, the MIP coated LPG sensor was washed with a solution of methanol/chloroform 
(50/50, v/v), pH=3.5) and dried under a stream of N2 gas.  
2-AQ MIP sensors (Dabrafenib analogue) were fabricated as these provided a cost-effective means of 
optimizing sensor parameters and also enabled rapid evaluation of any cross sensitivity of the 
Dabrafenib MIP sensors. These were prepared under identical conditions using the same methodology 
but with the following polymerization mixture: 2-AQ (14.4 mg, 100 µmol)  MAA (17.2 µL, 204 µmol), 
EGDMA (396 µL, 2.1 mmol) and PEGMA (65.4 µL, 143 µmol) and DMPA (20 mg, 78.1 µmol). 
 
2.5 Measurements of template binding specificity 
The bulk refractive index of different solvents can be a confounding issue for measurement of the LPG 
response in liquid 7. Accordingly, the responses of the bare LPG and MIP functionalized LPG in 
different buffer solutions were evaluated, with transmission spectra of two LPGs, before and after 
functionalization, being measured after immersion into DI-water, PBS and FBS, respectively. 
The behaviour of a non-imprinted LPG (NIP LPG) sensor was investigated by comparing the response 
of the 2-AQ imprinted LPG with the non-imprinted LPG. After fabrication, the two LPGs were 
immersed in 2-AQ solutions varying in concentration from 1.0-6.6 mg mL-1 and the LPG response 
measured by recording the wavelength shift over these concentrations.  
Similarly, the Dabrafenib molecularly imprinted polymer sensor (DAB MIP sensor) was exposed to 
variable concentrations of Dabrafenib (in PBS) by immersion into 0-1.0mg mL-1 of Dabrafenib until 
the measured signal does not change with further addition of the analyte. These ranges were chosen as 
the clinically observed concentration for a dose of 150mg/kg twice daily is ~2µM (1.0mg mL-1) 18,  In 
order to investigate cross sensitivity, the DAB MIP sensor was also exposed to varying concentrations 
of the 2-AQ analogue. 
After each exposure, the sensor was washed with acidified water with methanol/chloroform (1:1) to 
remove the Dabrafenib adsorbed to the MIPs, followed by thorough rinsing with DI-water and drying 
with N2. The transmission spectrum of the LPG sensor was acquired and recorded during the whole 
measurement using the spectrometer set-up as shown in Fig. 1c with a sampling frequency of 1 Hz. 
The wavelength shifts of the attenuation band of the PMTP were tracked from the recorded spectra. 
For the binding selectivity experiments, the DAB MIP sensor was exposed to 2-AQ (in PBS) with 
increasing concentrations up to 1 mg mL-1 and the bare LPG and 2-AQ MIP sensors were tested by 
exposure to variable concentrations of Dabrafenib (in PBS) and 2-AQ (in PBS) respectively.  
In order to mimic more closely conditions likely to be encountered in vivo, the DAB MIP sensor 
was tested by exposure to Dabrafenib in fetal bovine serum (FBS) at drug concentrations up to 750 µg 
mL-1 and 2-AQ in serum with concentration up to 500 µg mL-1. All experiments were conducted at 
20 °C in a temperature regulated laboratory to reduce the effects of temperature cross-sensitivity. The 
LoD is estimated as LoD=3*σ/S, where σ is the standard deviation of the measured signal and S is the 
sensitivity of the sensor derived from the calibration curve 19. 
 
3. Results and Discussion  
3.1. Design, preparation and characterisation of fibre coating MIP surfaces 
The aims of this study were to evaluate if molecularly imprinted polymers could be prepared on LPG 
surfaces to generate cavities with selective binding properties for target templates 17, and with the 
ability to transduce a signal from the binding events via a wavelength shift under conditions relevant 
to clinical monitoring. Accordingly, we developed an imprinting approach based on the key 
functionality in the analyte of interest, Dabrafenib, i.e. the 2-aminopyrimidine ring, which we expected 
to bind strongly to methacrylic acid, which is one of the most utilised monomers for molecular 
imprinting. The sensors were intended for use in aqueous conditions, thus in addition to methacrylic 
acid as the functional binding monomer, we included the water-soluble monomer poly(ethyleneglycol) 
methacrylate (PEGMA), in order to swell the MIP matrix in contact with serum, and allow easier 
access of the drug molecules into the recognition sites. In addition, PEGMA was included because of 
its strong enthalpic binding to water and entropic resistance to compression, helping to provide a 
barrier to adsorption of proteins, predominantly albumin, which otherwise cause fouling of materials 
in contact with serum components. Owing to the cost and potency of Dabrafenib, we optimised the 
initial fibre-coating and imprinting protocols using 2-aminoquinoline as an inexpensive analogue of 
Dabrafenib, with 2-aminopyridine functionality to serve as a model for imprinting the 2-
aminopyrimidine region of Dabrafenib (Figure 2). 
  
Figure 2: Schematic of potential binding modes for imprinting (A) of 2-aminoquinoline (2-AQ) and (B) 
Dabrafenib.  
The first step in the process was to functionalise the LPG surfaces with methacrylate functionality in 
order to form a reactive substrate for subsequent covalent anchoring of the MIP matrix. Cleaning of 
the LPG was performed via a Piranha solution etch and multiple washing steps prior to drying. The 
fibres were then reacted with 3-(trimethoxysilyl) propyl methacrylate (TMSPMA) and allowed to dry. 
ATR (attenuated total reflectance) FTIR spectra of the fibres (Figure 3) were recorded to confirm 
success of the silanization process. There was a weak attenuation band from υ(O-H) stretches between 
3200 and 3700 cm-1 on the silanized glass due to residual free hydroxyl groups, but also bands present 
at ~ 3000 cm-1 and 1720 cm-1, in the case of silanized glass due to υ(C-H) and υ(C=O ester) 
contributions, respectively.  
  
  
Figure 3. (A) ATR-FTIR spectra of bare glass (black), silanized glass (red) and silane liquid sample of TMSPMA (blue); 
(B) Transmission spectra of the deposition of MIP LPG sensor.    
 
A B
The transmission spectra were measured in air after each deposition process and normalised by taking 
an automatic baseline for each spectrum using MATLAB software. As shown in Fig. 3(b), after 
methacryloylsilanization (blue curve), there was a blue shift of linearly polarised (LP) mode LP020 
resonance, and the appearance of a dual attenuation band for LP020 mode resonance, which are 
characteristic of a thin film deposited onto the cladding of the LPG 7,13. It should be noted that further 
blue shifts of LP019 mode resonance and development of the dual attenuation band for LP020 resonance 
were observed, after the template imprinting stage (green trace shown in Fig. 3(b)), indicating 
successful coating of a MIP layer onto the LPG surface. The positions of the experimentally measured 
attenuation bands of an uncoated LPG (LP019 = 663.5nm,  LP020 = 819.7nm) are slightly different to 
those obtained using simulation with Optigrating 4.2.2 (LP019 = 655nm,  LP020 = 830nm). This may be 
attributed to the deviation of the real fibre refractive index value from the optical fiber datasheet values 
or uncertainties in the LPG fabrication process (error in length or period). It should be noted that all 
drug concentration measurements were made relative to this baseline and so the absolute position does 
not affect the measurement.  
The effects on the bulk refractive index of the fibres in response to immersion in solutions and assay 
media were evaluated and shown in Figure 4. In the Figure, each column shows the wavelength shift 
of the trough position for the LP020 mode resonance left band, as the solution in which the fibres were 
immersed was switched from DI-water to the assay solvent. These data indicated there were changes 
in the resonances of 0.2 nm and 1.5 nm in PBS and FBS, respectively, both in the bare LPG and 
Dabrafenib MIP LPG (DAB MIP LPG) case. Higher response for both functionalised and non-
functionalised sensors in FBS as compared to PBS is most plausibly due to the higher refractive index 
(RI) of the FBS. The RI values of DI-water, PBS and FBS is 1.3301, 1.3350 and 1.3464 respectively 
measured by digital refractometer (Reichert, Brix/RI-Chek, Japan). The response of the MIP LPG was 
in agreement with that of the bare LPG within the range of error bars, demonstrating that the MIP LPG 
was not adversely affected by any non-specific interaction with the salts in PBS and additional proteins 
in FBS in this case.  
 
Figure 4: (A) Comparison of the response between bare and Dabrafenib MIP coated LPG in different solvents, DI-
water, PBS and FBS,(B) 2-AQ tests of imprinted LPG and non-imprinted LPG.  Error bars represent standard deviation.  
The performance of the two sensor fibres was investigated by comparing the response to the 
Dabrafenib analogue 2-AQ of an LPG polymer imprinted with 2-AQ (2-AQ MIP LPG) and a non-
imprinted polymer LPG (NIP LPG). The imprinted LPG was fabricated by following the steps in 
section 2.2 whereas the NIP LPG was made with the identical protocol but without adding the template. 
After fabrication, the two LPGs were immersed in the same concentration of 2-AQ solution (e.g. 1 mg 
mL-1 in PBS) firstly and the LPG response was monitored after increasing the 2-AQ concentration to 
a higher level (e.g. 6.6 mg mL-1 in PBS). Figure 4B shows the results comparing the optical response 
of the LPG fibres of the MIP and NIP sensors. The separations of the LP020 resonance dual band for 
each sensor was measured in DI-water and at two different concentrations of template solution (2-AQ 
in this case). It was seen that the MIP sensor exhibited a wavelength shift of 0.80 and 3.7 nm for 1 mg 
mL-1 and 6.6 mg mL-1 concentration of 2-AQ solution, respectively. In contrast, the response of NIP 
sensor did not significantly change over the different concentrations of target 2-AQ analyte (0.34 and 
0.16 nm for 1 mg mL-1 and 6.6 mg mL-1 of 2-AQ solution) in LP020 dual band separation (Fig 4B). 
These results suggest that there is higher affinity for the analyte in the MIP sensor compared to the 
NIP sensor, confirming the presence of selective binding sites for 2-AQ as a consequence of the 
imprinting process in the MIP and induction of molecular recognition in this system. 
 
3.2.Evaluation of imprinting selectivity 
The MIP LPG sensor was subsequently exposed to increasing concentrations of Dabrafenib in PBS 
solution. As shown in Fig. 5A, with the increase in target analyte concentration, the LP020 resonance 
dual-band (L-LP020 and R-LP020) becomes broader and there is a blue shift for the LP019 resonance 
band indicating RI increase during the binding process. The dynamic wavelength shift for the 
separation of dual-band in Fig. 4B demonstrated an increase in the amount of Dabrafenib bound to the 
DAB MIP sensor surface, which exhibited wavelength shifts of 0.31, 0.88, 1.26, 3.30, 6.33 and 13.40 
nm for the 10, 50, 100, 250, 500 and 1000µg mL-1 Dabrafenib concentrations, respectively.  
 
Figure 5: (A)  Transmission spectra of DA MIP sensor with different concentrations of Dabrafenib solution in aqueous buffer solutions; 
(B) selectivity and sensitivity comparison for the sensors (error bars are the standard deviation of each measurement). The dynamic 
change of LP020 band separation for Dabrafenib MIP LPG sensor is shown in (C) Dabrafenib and (D) 2-AQ measurement; (E) and (F) is 
Dabrafenib and 2-AQ measurement using bare LPG; (G) and (H) represent Dabrafenib and 2-AQ measurement using 2-AQ MIP sensor.  
Compared with the DAB MIP sensor, the LP020 dual band response in the bare LPG case (Fig. 5E) and 
(5F) did not show a significant wavelength shift with increasing concentrations of target templates, as 
expected. In addition, for the 2-AQ MIP sensor measurements, shown in Fig. 5G and 5H, the responses 
were calculated by taking the average of the signal remaining at a constant level in each concentration, 
showing wavelength shifts of 0.14, 0.22, 0.30, 0.39 and 0.69 nm for the 62.5, 125, 250, 500 and 1000 
µg mL-1 2-AQ concentrations and 0.06, 0.28, 0.49 and 0.59 nm for the 125, 250, 500 and 1000 µg mL-
1 Dabrafenib concentrations, respectively. Fig 5B depicts the total sensitivity comparison between bare 
LPG, 2-AQ and DAB MIP LPG, indicating that the DAB MIP sensor demonstrated selectivity and 
good sensitivity to Dabrafenib of 13.2pm/(μg·mL-1) (R2=0.998).   
 
3.3 Detection of Dabrafenib in serum 
To evaluate the performance of the prepared DAB MIP sensor under more clinically relevant 
conditions, measurements were conducted to detect Dabrafenib and 2-AQ in FBS.  In Fig 6A it can be 
seen that the LP020 band separation changes during the whole Dabrafenib measurement, which 
exhibited wavelength shifts of 0.25, 0.76, 1.63, 2.62, 4.77, 7.97 and 11.87 nm for the 10, 20, 50, 100, 
250, 500 and 750 µg mL-1 Dabrafenib concentrations in FBS, respectively. For comparison, the DAB 
MIP sensor was also exposed to a range of concentrations of 2-AQ in FBS, and the wavelength shifts 
changed by1.26nm at a concentration of 2-AQ of 500 µg mL-1.  
 
Figure 6: The dynamic change of LP020 band separation for Dabrafenib MIP LPG sensor is shown in (A) Dabrafenib and 
(B) 2-AQ measurement; (C) sensitivities comparison for the sensor in Dabrafenib and 2-AQ measurement. 
This response of the Dabrafenib sensor to 2-AQ was also apparent in PBS as well, indicating a small 
amount of non-specific association of 2-AQ with the DAB MIP. This was not unexpected considering 
the designed structural similarities, but this binding was much less than Dabrafenib at all 
concentrations. Overall, the DAB MIP fibres exhibited sensitivities in serum to Dabrafenib and 2-AQ 
of 15.2pm/(μg·mL-1) (R2=0.993) with limit of detection (LoD) of 74.4 μg·mL-1 and 2.5pm/(μg·mL-1) 
(R2=0.994), respectively.  
Clinically relevant ranges of dabrafenib in plasma are approximately 6 g.mL-1 20 and based on the 
LoD from the raw data our sensor currently falls outside this range. Estimation of the LoD calculation 
depends on the sensitivity of the sensor and the noise level of the data (Section 2.5). Some simple 
signal processing can reduce the noise levels and the estimated LoD. For example, applying a Moving 
Average Filter (MAF) in the time domain with a 20 or 100 data points calculation window can be used 
to reduce the noise (σ) from 320pm to 57.9pm (20 pts) or 8.66pm (100 pts), respectively. Subsequently, 
the estimated LoD is reduced from 74.4 to 11.4 (20 pts) or 1.71 µg.mL-1 (100 pts). Further 
improvements to the configuration of the sensor can also be made, for example, MIP nanoparticles 7 
have shown higher sensitivity due to spherical morphology and offer a promising direction for further 
investigation. 
Translation of the technology in vivo will require measurements to be made at body temperature, 
which is higher than the ambient temperature used here. However, it should be noted that high stability 
against non-physiological conditions such as high temperature is one of the advantages of MIPs 21 22. 
Furthermore, a study by Svenson et al demonstrated that the molecularly imprinted MAA & EGDMA 
polymers, monomer and cross-linker also used in this work, have been shown to be able to withstand 
exposure to temperatures of up to 150 °C without loss of affinity for their template 23. Therefore, the 
MIP in this work should be able to operate in ~36 °C (in-vivo temperature). This will be investigated 
in more detail as we translate the technology in vivo. It should also be noted that LPGs are known to 
have cross-sensitivity to temperature. As shown in this paper, this can be addressed in laboratory 
conditions by controlling the environmental temperature. For in vivo use, an additional LPG can be 
used for temperature compensation 24 25. Coating the reference LPG with a non-imprinted polymer will 
ensure the thermal properties of the polymer are accounted for. 
 
Conclusions 
Specific detection of Dabrafenib has been demonstrated using a long period grating optical fibre sensor 
functionalised with a molecularly imprinted polymer. The sensor demonstrated high sensitivity in 
serum of 15.2pm/(μg·mL-1) (R2=0.993) with a LoD of 74.4 μg·mL-1 when exposed to varying 
concentrations of Dabrafenib in serum. In principle, the sensitivity could be further reduced to 1.71 
µg.mL-1 with additional signal processing, which is well within the range required clinically. The 
selectivity of the proposed sensor was also investigated by comparing the response of the 
functionalised LPG to Dabrafenib and a structurally similar compound, 2-AQ. The DAB MIP sensor 
shows a weak sensitivity to 2-AQ (2.5pm/(μg·mL-1)) in serum as compared to Dabrafenib 
(15.2pm/(μg·mL-1)). In addition, the response of LPG functionalised with non-imprinting molecularly 
imprinted polymer to both Dabrafenib and structurally similar compound, 2-AQ was negligible 
indicting low non-specific binding. Future work will involve development of the sensor into a 
minimally invasive tool for measurement at a tumour site.  
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